Almac completes £2 million client sponsored investment expanding commercial sacheting capacity
June 14, 2010
Meeting our client partner’s commercial need for additional sachet capacity, Almac completes a £2 million investment program.
Almac Pharma Services have today announced the completion of a client sponsored capital investment of £2 million at the company’s commercial facilities at the Group’s headquarters in Craigavon, Northern Ireland.
Annualized output will be in excess of 120 million sachets, split across various packed formats.
Geoff Sloan, VP Manufacturing Operations of Almac Pharma Services said: “This investment has allowed our client to quickly meet growing demand for one of their key future products. Utilizing Almac’s technical and project management expertise to deliver a complex engineering solution to an aggressive project timeline will assist our client in securing the market for this strongly performing product.”
Graeme McBurney, President and M.D of Almac Pharma Services said: “This level of investment demonstrates our commitment to building long term, strategic relationships with our client partners.”
Almac Pharma Services
Tel: +44 2838 363363
Tel: + 44 2078 613019
About Almac Group
The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, translational genomic services, API manufacture, formulation development, clinical trial supply and technology (IVRS & Web), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.
The company employs over 2,600 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Construction of the company’s new $120m North American Headquarters started in July 08 and is expected to be completed 2010. Almac was awarded Northern Ireland’s “Business of the Year” award in 2009.